NCT04825990View on ClinicalTrials.gov

Pembrolizumab and Olaparib in Recurrent/Metastatic, Platinum Resistant Nasopharyngeal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 24, 2022

Primary Completion Date

September 24, 2025

Study Completion Date

March 24, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Pembrolizumab

200 mg pembrolizumab every 3 weeks plus 300 mg olaparib twice a day (BID) every day starting from Day 1 of Cycle 1.

Trial Locations (1)

25123

RECRUITING

Asst Degli Spedali Civili Di Brescia, Brescia

All Listed Sponsors
lead

Gruppo Oncologico del Nord-Ovest

OTHER